Comparing CRISPR Therapeutics (NASDAQ:CRSP) & Lifecore Biomedical (NASDAQ:LFCR)

CRISPR Therapeutics (NASDAQ:CRSP) and Lifecore Biomedical (NASDAQ:LFCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Earnings and Valuation

This table compares CRISPR Therapeutics and Lifecore Biomedical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	1,484.12	-$581.60 million	($6.22)	-8.68
Lifecore Biomedical	$128.87 million	1.31	-$35.26 million	($0.94)	-4.79

Lifecore Biomedical has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares CRISPR Therapeutics and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%

Analyst Ratings

This is a summary of current recommendations for CRISPR Therapeutics and Lifecore Biomedical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2	5	10	1	2.56
Lifecore Biomedical	1	2	2	0	2.20

CRISPR Therapeutics currently has a consensus target price of $66.06, indicating a potential upside of 22.32%. Lifecore Biomedical has a consensus target price of $6.00, indicating a potential upside of 33.33%. Given Lifecore Biomedical’s higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than CRISPR Therapeutics.

Volatility and Risk

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Summary

Lifecore Biomedical beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.